HomeAI · summaries
Storia in 3 fonti
Fierce Pharma Asia—More AZ China deals; Kailera, Hengrui’s oral GLP-1 data; Scrutiny of Chinese trials
In the two weeks before and after Independence Day in the U.S., AstraZeneca signed potential billion-dollar licensing deals with CSPC Pharmaceutical and Sino Biopharmaceutical, Hengrui Pharma's Kal | AstraZeneca signed potential billion-dollar licensing deals with CSPC and Sino Biopharm, Hengrui's Kaleira-partnered oral GLP-1 candidate reported obesity and diabetes phase 3 data from China, and biotech insiders decried certain U.S. lawmakers' scrutiny over Chinese clinical trials as a distraction. And more.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
AstraZeneca, GSK intensify China ties with Sino Biopharm deals
The U.K. drugmakers added to a series of recent tie-ups with Chinese counterparts amid broader scrutiny of such transactions in the U.S.
- ·
statnews.com
Europe will accelerate its review of RevMed's drug
Kailera's GLP-1 pill data raises concerns, FDA clears Vera autoimmune therapy, and more biotech news from The Readout
